News

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide.

Grenova and its division partners are backed by healthcare-focused private equity firm Peloton Equity.

Hull brings more than 30 years of leadership experience in the life sciences and diagnostics industries and has served on the Grenova Board of Directors for the past 13 months. He previously served as CEO of Bako Diagnostics and Genova Diagnostics – a former FFC company, Peloton’s predecessor firm – and has worked closely with Peloton Equity as an operating partner.

“Given the increasing demand for automation across laboratory workflows, this is a particularly exciting time to build a scaled, integrated platform in this space. Grenova, Peak Robotics, and PAA each bring world-class capabilities in their respective fields, creating a unique set of solutions for our customers,” said Ted Hull. “I’m incredibly excited to work alongside this team to shape the future of scientific automation.”

“We’re thrilled to partner with Ted again,” said Michael O’Rourke, Partner at Peloton Equity. “Ted brings a rare combination of operational leadership, industry expertise, and a deep understanding of how to scale growth companies. Having worked closely with the company and served alongside the leadership team, he is uniquely positioned to lead this next phase of growth.”

With the combined capabilities of Grenova’s technologies and the automation and integration expertise of Peak Robotics and PAA, the organization is positioned to deliver modular, scalable solutions and become a global leader in laboratory automation.

Read more here.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,